



FUSION PHARMA LTD.

FOUNDED

in **2011**

[Grant received]

CORE OF THE INNOVATION

To receive an innovative medicine for the therapy of chronic myeloid leukemia and its resistant forms.

IMPLEMENTATION OF THE TECHNOLOGY

ALREADY IN **2016**

PEOPLE

GENERAL DIRECTOR:

Germes G. Chilov, PhD in Chemistry

1

Applications

Potential extra indications for using the medicine:

- patients with thyroid cancer and with mutations in RET kinase gene;
- patients with non-small cell carcinoma of lung with mutations in ROS and DDR kinase;
- patients with gastrointestinal stromal tumors with mutations in PDGFRA and c-Kit kinase.

2

Peculiarities of the product

Peculiarity of the drug candidate made by our company is in its effectiveness against all resisting mutant forms of the chronic myeloid leukemia known for today.

3

Market estimation

Market of the Russian Federation for the indication “chronic myeloid leukemia” is 150 mln. USD, and the world market makes up around 5 bln. USD. The fastest possible introduction of the innovation is possible in our country.

